{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T13:56:32Z","timestamp":1752674192470,"version":"3.38.0"},"reference-count":48,"publisher":"Oceanside Publications Inc.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> The data on subphenotypes and treatment responses to biologicals in late-onset asthma (LOA) is limited. This study aims to compare the clinical characteristics and treatment responses in severe asthma patients receiving biological treatments, categorized into\n early-onset asthma (EOA) and LOA groups.  <jats:bold>Methods:<\/jats:bold> Patients treated with omalizumab or mepolizumab for at least six months at a tertiary care adult allergy clinic between December 2015 and December 2023 were included. Patients with persistent respiratory symptoms starting\n at age \u226540 years were categorized as LOA, while those with onset &lt;40 years were categorized as EOA. Changes in Asthma Control Questionnaire (ACQ-6) scores, forced expiratory volume in one second (FEV1) percentages, and blood eosinophil counts were assessed at baseline and 6 months. The\n percentage change in FEV1 (liters) at 6 months relative to baseline was measured. Clinical remission rates were evaluated in those completing one year of treatment.  <jats:bold>Results:<\/jats:bold> Among 87 patients, 38 (43.7%) had LOA and 49 (56.3%) had EOA. Of these, 22 (25.3%) received omalizumab\n and 65 (74.7%) received mepolizumab, with a mean treatment duration of 24.7 (\u00b119.7) months. LOA patients had higher obesity rates and tobacco consumption compared to EOA patients (p = 0.041 and p = 0.024, respectively). There were no significant differences between LOA and EOA groups\n in ACQ scores, FEV1 percentage, the percentage change in FEV1 in liters and eosinophil counts (p = 0.531, p = 0.219, p = 0.632, p = 0.700, respectively). Within LOA patients, ACQ scores did not significantly differ between those treated with omalizumab and mepolizumab (p = 0.801). At 6 months,\n eosinophil counts significantly decreased with mepolizumab but not with omalizumab (p = 0.002).  <jats:bold>Conclusion:<\/jats:bold> Biological treatment responses were similar between LOA and EOA groups. Omalizumab and mepolizumab showed comparable efficacy, with the exception of eosinophil count\n changes in LOA patients.<\/jats:p>","DOI":"10.2500\/aap.2025.46.240105","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T04:31:02Z","timestamp":1740630662000},"page":"109-118","source":"Crossref","is-referenced-by-count":2,"title":["Clinical characteristics and biological treatment responses of patients with late-onset asthma phenotype"],"prefix":"10.2500","volume":"46","author":[{"given":"Hazal","family":"Kayikci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebru","family":"Damadoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melek","family":"Cihanbeylerden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cise","family":"Tuccar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gul","family":"Karakaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Fuat","family":"Kalyoncu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-2600(17)30293-X","article-title":"Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"5","year":"2017","journal-title":"Lancet Respir Med"},{"key":"B2","article-title":"Global initiative for asthma 2024"},{"key":"B3","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nm.2678","article-title":"Asthma phenotypes: the evolution from clinical to molecular approaches","volume":"18","author":"Wenzel","year":"2012","journal-title":"Nat Med"},{"key":"B4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2003.10.041","article-title":"Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation","volume":"113","author":"Miranda","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1136\/bmj.300.6740.1602","article-title":"Late onset asthma","volume":"300","author":"Ayres","year":"1990","journal-title":"BMJ"},{"key":"B6","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/JAA.S282205","article-title":"Revisiting late-onset asthma: clinical characteristics and association with allergy","volume":"13","author":"Quirce","year":"2020","journal-title":"J Asthma Allergy"},{"key":"B7","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.jaip.2022.03.019","article-title":"Characterization of asthma by age of onset: a multi-database cohort study","volume":"10","author":"Baan","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B8","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jaip.2017.01.027","article-title":"Cluster analysis on longitudinal data of patients with adult-onset asthma","volume":"5","author":"Ilmarinen","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/all.13599","article-title":"Diagnosis and management of NSAID-exacerbated espiratory disease (N-ERD)\u2014a EAACI position paper","volume":"74","author":"Kowalski","year":"2019","journal-title":"Allergy"},{"key":"B10","doi-asserted-by":"crossref","first-page":"107348","DOI":"10.1016\/j.rmed.2023.107348","article-title":"Severe asthma clinical remission after biologic treatment with anti-IL4\/IL13: a real-life experience","volume":"217","author":"Portacci","year":"2023","journal-title":"Respir Med"},{"key":"B11","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/all.13850","article-title":"The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma","volume":"74","author":"Chapman","year":"2019","journal-title":"Allergy"},{"key":"B12","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/cea.14389","article-title":"Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitization","volume":"53","author":"Corren","year":"2023","journal-title":"Clin Exp Allergy"},{"key":"B13","doi-asserted-by":"crossref","first-page":"100934","DOI":"10.1016\/j.waojou.2024.100934","article-title":"Comparative efficacy of biologics for patients with inadequately controlled asthma: a network meta-analysis","volume":"17","author":"Kim","year":"2024","journal-title":"World Allergy Organ J"},{"key":"B14","first-page":"7461","article-title":"Severe asthma and long-term benralizumab effectiveness in real-life","volume":"26","author":"Sposato","year":"2022","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B15","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.anai.2023.08.609","article-title":"Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment","volume":"131","author":"Blaiss","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B16","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1016\/j.jaip.2023.07.041","article-title":"Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: a Delphi Consensus","volume":"11","author":"Canonica","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B17","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/all.12136","article-title":"Three phenotypes of adult-onset asthma","volume":"68","author":"Amelink","year":"2013","journal-title":"Allergy"},{"key":"B19","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jaci.2013.04.052","article-title":"Severe adult-onset asthma: a distinct phenotype","volume":"132","author":"Amelink","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1164\/rccm.200906-0896OC","article-title":"Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program","volume":"181","author":"Moore","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"B21","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/all.13342","article-title":"RitA: the Italian Severe\/Uncontrolled Asthma Registry","volume":"73","author":"Maio","year":"2018","journal-title":"Allergy"},{"key":"B22","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jaip.2018.10.016","article-title":"The Severe Asthma Network in Italy: findings and perspectives","volume":"7","author":"Heffler","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/JAA.S125948","article-title":"Late-onset asthma: current perspectives","volume":"11","author":"Hirano","year":"2018","journal-title":"J Asthma Allergy"},{"key":"B24","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1183\/13993003.00850-2016","article-title":"The effect of smoking on lung function: a clinical study of adult-onset asthma","volume":"48","author":"Tommola","year":"2016","journal-title":"Eur Respir J"},{"key":"B25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.55730\/1300-0144.5792","article-title":"Elderly and aged asthma have different characteristics: results of a multicenter study","volume":"54","author":"Damado\u011flu","year":"2024","journal-title":"Turk J Med Sci"},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00100-2015","article-title":"Clinical profile of patients with adult-onset eosinophilic asthma","volume":"2","author":"de Groot","year":"2016","journal-title":"ERJ Open Res"},{"key":"B27","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.iac.2016.06.002","article-title":"Clinical characteristics of aspirin-exacerbated respiratory disease","volume":"36","author":"Stevenson","year":"2016","journal-title":"Immunol Allergy Clin North Am"},{"key":"B28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.autrev.2014.12.004","article-title":"Churg-Strauss syndrome","volume":"14","author":"Greco","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B29","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s11739-021-02863-0","article-title":"The clinical features and treatment of eosinophilic granulomatosis with polyangiitis (EGPA) in Turkey: one or two distinct diseases?","volume":"17","author":"Duran","year":"2022","journal-title":"Intern Emerg Med"},{"key":"B30","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/cea.13790","article-title":"Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma","volume":"51","author":"Chen","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"B31","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaip.2017.06.015","article-title":"Subphenotypes of type 2 severe asthma in adults","volume":"6","author":"Matsusaka","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B32","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1016\/j.jaip.2021.01.011","article-title":"Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies","volume":"9","author":"Bousquet","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/5584_2016_29","article-title":"Monoclonal antibodies for the management of severe asthma","volume":"935","author":"Rubinsztajn","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"B35","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B36","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/all.14221","article-title":"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI guidelines - recommendations on the use of biologicals in severe asthma","volume":"75","author":"Agache","year":"2020","journal-title":"Allergy"},{"key":"B37","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.3390\/jcm12082900","article-title":"A real-world study of achievement rate and predictive factors of clinical and deep remission to biologics in patients with severe asthma","volume":"12","author":"Oishi","year":"2023","journal-title":"J Clin Med"},{"key":"B38","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.chest.2023.01.037","article-title":"Sputum type 2 markers could predict remission in severe asthma treated with anti-IL-5","volume":"163","author":"Moermans","year":"2023","journal-title":"Chest"},{"key":"B39","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.jaip.2023.05.047","article-title":"Response to biologics and clinical remission in the adult German Asthma Net Severe Asthma Registry cohort","volume":"11","author":"Milger","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B40","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1111\/all.15693","article-title":"Factors associated with suboptimal response to monoclonal antibodies in severe asthma","volume":"78","author":"P\u00e9rez de Llano","year":"2023","journal-title":"Allergy"},{"key":"B41","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2023.01.020","article-title":"Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: a target trial emulation","volume":"151","author":"Akenroye","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B42","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1159\/000539310","article-title":"Comparison of the efficacy of omalizumab and mepolizumab in non-steroidal anti-inflammatory drug-exacerbated respiratory disease","volume":"185","author":"Cihanbeylerden","year":"2024","journal-title":"Int Arch Allergy Immunol"},{"key":"B43","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.rmed.2016.12.009","article-title":"Comparative effectiveness of mepolizumab and omalizumab in severe asthma: an indirect treatment comparison","volume":"123","author":"Cockle","year":"2017","journal-title":"Respir Med"},{"key":"B44","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/all.16002","article-title":"Lung function trajectories in a cohort of patients with moderate-to-severe asthma on mepolizumab, omalizumab, or dupilumab","volume":"79","author":"Nopsopon","year":"2024","journal-title":"Allergy"},{"key":"B45","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2147\/JAA.S476774","article-title":"Reduced effectiveness of anti-IgE treatment among adults with severe asthma with older age of asthma onset: results from the CHRONICLE study","volume":"17","author":"Ledford","year":"2024","journal-title":"J Asthma Allergy"},{"key":"B46","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","article-title":"Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study","volume":"7","author":"Casale","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B47","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1080\/02770903.2023.2196567","article-title":"Comparison of the clinical outcomes of patients with NSAID-exacerbated respiratory disease receiving aspirin or biologicals","volume":"60","author":"Tuncay","year":"2023","journal-title":"J Asthma"},{"key":"B48","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1183\/09031936.00012415","article-title":"Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes","volume":"46","author":"Westerhof","year":"2015","journal-title":"Eur Respir J"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2025\/00000046\/00000002\/art00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T04:34:01Z","timestamp":1741149241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2025.46.240105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3,1]]}},"alternative-id":["1088-5412(20250301)46:2L.109;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2025.46.240105","relation":{},"ISSN":["1088-5412"],"issn-type":[{"type":"print","value":"1088-5412"}],"subject":[],"published":{"date-parts":[[2025,3,1]]}}}